Related references
Note: Only part of the references are listed.A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913
Prakash Chinnaiyan et al.
NEURO-ONCOLOGY (2018)
Phase 1/2 Trial of Temsirolimus and Sorafenib in the Treatment of Patients With Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572
David Schiff et al.
CANCER (2018)
MANTA - A randomized phase II study of fulvestrant in combination with the dual mTOR inhibitor AZD2014 or everolimus or fulvestrant alone in estrogen receptor-positive advanced or metastatic breast cancer
Peter Schmid et al.
CANCER RESEARCH (2018)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2018)
The Akt/mTOR pathway in cancer stem/progenitor cells is a potential therapeutic target for glioblastoma and neuroblastoma
Hisham F. Bahmad et al.
Oncotarget (2018)
Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence
Carmen Mecca et al.
DISEASE MARKERS (2018)
Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study
Vasilios Karavasilis et al.
TARGETED ONCOLOGY (2018)
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development
Hua-fu Zhao et al.
MOLECULAR CANCER (2017)
Lomustine and Bevacizumab in Progressive Glioblastoma
Wolfgang Wick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082)
Wolfgang Wick et al.
CLINICAL CANCER RESEARCH (2016)
A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer
Thomas Powles et al.
EUROPEAN UROLOGY (2016)
PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma
Xiaoman Li et al.
ONCOTARGET (2016)
Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2015)
Enhanced cytotoxic effect of radiation and temozolomide in malignant glioma cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone deacetylases
Eun Jung Choi et al.
BMC CANCER (2014)
Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival
H. Artee Luchman et al.
CLINICAL CANCER RESEARCH (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014
Kurt G. Pike et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Development of PI3K inhibitors: lessons learned from early clinical trials
Jordi Rodon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2013)
Rapalogs in cancer prevention Anti-aging or anticancer?
Mikhail V. Blagosklonny
CANCER BIOLOGY & THERAPY (2012)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Activated Phosphoinositide 3-Kinase/AKT Signaling Confers Resistance to Trastuzumab but not Lapatinib
Neil A. O'Brien et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
New (alternative) temozolomide regimens for the treatment of glioma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2009)
S6K1 plays a key role in glial transformation
Jean L. Nakamura et al.
CANCER RESEARCH (2008)
Chemoradiotherapy in malignant glioma: Standard of care and future directions
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phosphatase and tensin homologue deficiency in giloblastoma confers resistance to radiation and temozolomide that is reversed by the protease inhibitor nelfinavir
Zibin Jiang et al.
CANCER RESEARCH (2007)
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2007)
Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo
H Momota et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme
JS Smith et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
PTEN is a target of chromosome 10q loss in anaplastic oligodendrogliomas and PTEN alterations are associated with poor prognosis
H Sasaki et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
